CRUPI, EMANUELE
CRUPI, EMANUELE
Facoltà di Medicina e Chirurgia
Bladder Preservation After Neoadjuvant Therapy for Muscle-invasive Bladder Cancer in the Current Era: Myth and Reality
2026-01-01 Crupi, Emanuele; Necchi, Andrea; Kamat, Ashish M
Comprehensive genomic profiling (CGP) of clinical T2-4N0M0 muscle-invasive bladder cancer (MIBC) treated with neoadjuvant pembrolizumab or cisplatinbased chemotherapy before radical cystectomy (RC)
2024-01-01 Mercinelli, C.; Raggi, D.; Cigliola, A.; Tateo, V.; Patane, D. A.; Crupi, E.; Colecchia, M.; Moschini, M.; Re, C.; Avesani, G.; Briganti, A.; Montorsi, F.; Ross, J. S.; Graf, R.; Pavlick, D. C.; Necchi, A.
Data from Impact of Molecular Androgen and Estrogen Response Scores on Outcomes Following Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer
2025-01-01 Tateo, Valentina; De Jong, Joep J.; Cigliola, Antonio; Maiorano, Brigida A.; Mercinelli, Chiara; Crupi, Emanuele; Giannatempo, Patrizia; Colecchia, Maurizio; Moschini, Marco; Proudfoot, James A.; Santini, Daniele; Davicioni, Elai; Briganti, Alberto; Montorsi, Francesco; Necchi, Andrea
Data from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
2023-01-01 Basile, Giuseppe; Bandini, Marco; Gibb, Ewan A.; Ross, Jeffrey S.; Raggi, Daniele; Marandino, Laura; Costa De Padua, Tiago; Crupi, Emanuele; Colombo, Renzo; Colecchia, Maurizio; Lucianò, Roberta; Nocera, Luigi; Moschini, Marco; Briganti, Alberto; Montorsi, Francesco; Necchi, Andrea
Distinct Gene Expression Patterns Identify Patients who Relapse After Neoadjuvant Pembrolizumab and Radical Cystectomy in the PURE-01 Study
2024-01-01 Reike, M. J.; Raggi, D.; Mercinelli, C.; Cigliola, A.; Tateo, V.; Patanè, D. A.; Crupi, E.; De Padua, T. C.; Black, P. C.; Gibb, E. A.; Necchi, A.
First results of NURE-Combo: A phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with muscle-invasive bladder cancer (MIBC)
2024-01-01 Mercinelli, C.; Basile, G.; Raggi, D.; Cigliola, A.; Tateo, V.; Patanè, D. A.; Crupi, E.; Padua, T. C. D.; Colecchia, M.; Colombo, R.; Moschini, M.; Re, C.; Avesani, G.; Brembilla, G.; De Cobelli, F.; Briganti, A.; Pavlick, D. C.; Ross, J. S.; Montorsi, F.; Necchi, A.
HER2 and urothelial carcinoma: current understanding and future directions
2026-01-01 Raggi, Daniele; Crupi, Emanuele; Pederzoli, Filippo; Martini, Alberto; Briganti, Alberto; Alhalabi, Omar; O'Donnell, Peter H; Ross, Jeffrey; Gupta, Shilpa; Kamat, Ashish M; Faltas, Bishoy M; Black, Peter C; Spiess, Phillip E; Grivas, Petros; Gao, Jianjun; Apolo, Andrea B; Huddart, Robert A; Necchi, Andrea; Galsky, Matthew D
Impact of Molecular Androgen and Estrogen Response Scores on Outcomes Following Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer
2025-01-01 Tateo, V.; De Jong, J. J.; Cigliola, A.; Maiorano, B. A.; Mercinelli, C.; Crupi, E.; Giannatempo, P.; Colecchia, M.; Moschini, M.; Proudfoot, J. A.; Santini, D.; Davicioni, E.; Briganti, A.; Montorsi, F.; Necchi, A.
Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review
2024-01-01 Crupi, E.; Costa De Padua, T.; Marandino, L.; Fallara, G.; Pederzoli, F.; Cimadamore, A.; Goetz, E. C.; Cigliola, A.; Patane, D. A.; Mercinelli, C.; Tateo, V.; Salonia, A.; Briganti, A.; Montorsi, F.; Meeks, J. J.; Spiess, P. E.; Alhalabi, O.; Gao, J.; Kamat, A. M.; Grivas, P.; Necchi, A.; Raggi, D.
Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI
2024-01-01 Brembilla, G.; Basile, G.; Cosenza, M.; Giganti, F.; Del Prete, A.; Russo, T.; Pennella, R.; Lavalle, S.; Raggi, D.; Mercinelli, C.; Tateo, V.; Cigliola, A.; Patane, D.; Crupi, E.; Giannatempo, P.; Messina, A.; Calareso, G.; Martini, A.; Bandini, M.; Moschini, M.; Cardone, G.; Briganti, A.; Montorsi, F.; Necchi, A.; De Cobelli, F.
Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial
2022-01-01 Basile, Giuseppe; Bandini, Marco; Gibb, Ewan A; Ross, Jeffrey S; Raggi, Daniele; Marandino, Laura; Costa de Padua, Tiago; Crupi, Emanuele; Colombo, Renzo; Colecchia, Maurizio; Lucianò, Roberta; Nocera, Luigi; Moschini, Marco; Briganti, Alberto; Montorsi, Francesco; Necchi, Andrea
Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial
2026-01-01 Necchi, A.; De Jong, J. J.; Maiorano, B. A.; Proudfoot, J. A.; Basile, G.; Cigliola, A.; Mercinelli, C.; Tateo, V.; Piacentini, M.; Crupi, E.; Pastorino, G. L.; Latini, G.; Tomasi, E.; Davicioni, E.; Moschini, M.; Brembilla, G.; Colecchia, M.; De Cobelli, F.; Ross, J. S.; Madison, R.; Tambaoan, C. F. B.; Briganti, A.; Montorsi, F.
Targeting HER2 in Urothelial Carcinoma: Why Histologic Subtypes and Divergent Histologies Matter
2026-01-01 Crupi, Emanuele; Cigliola, Antonio; Mercinelli, Chiara; Piacentini, Michela; Serafin, Debora; Maiorano, Brigida A; Necchi, Andrea
Targeting the Immune Checkpoint in Bladder Cancer
2025-01-01 Mercinelli, C.; Tateo, V.; Crupi, E.; Cigliola, A.; Necchi, A.
The role of androgen response pathway in association with tumor biology and response to neoadjuvant immune-checkpoint inhibitors (ICI) in muscle-invasive urothelial bladder carcinoma (MIBC)
2024-01-01 Tateo, V.; Gibb, E.; Mercinelli, C.; Raggi, D.; Cigliola, A.; Patane, D. A.; Crupi, E.; Giannatempo, P.; Colecchia, M.; Moschini, M.; Avesani, G.; Briganti, A.; Montorsi, F.; Santini, D.; Necchi, A.
Utility of fluoro-deoxy-glucose positron emission tomography (FDG-PET) to predict a pelvic lymph node involvement (LNI) in patients (pts) with muscle-invasive bladder cancer (MIBC) enrolled in neoadjuvant therapy trials
2024-01-01 Cigliola, A.; Basile, G.; Mercinelli, C.; Raggi, D.; Tateo, V.; Patane, D. A.; Crupi, E.; Colecchia, M.; Colombo, R.; Avesani, G.; Re, C.; Briganti, A.; Montorsi, F.; Necchi, A.
Vesical Imaging-Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer
2024-01-01 Necchi, A.; Basile, G.; Gibb, E. A.; Raggi, D.; Calareso, G.; De Padua, T. C.; Patane, D.; Crupi, E.; Mercinelli, C.; Cigliola, A.; Tateo, V.; Giannatempo, P.; Moschini, M.; Briganti, A.; Montorsi, F.; Messina, A.; Ross, J. S.; Pavlick, D.; De Cobelli, F.; Brembilla, G.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Bladder Preservation After Neoadjuvant Therapy for Muscle-invasive Bladder Cancer in the Current Era: Myth and Reality | 1-gen-2026 | Crupi, Emanuele; Necchi, Andrea; Kamat, Ashish M | |
| Comprehensive genomic profiling (CGP) of clinical T2-4N0M0 muscle-invasive bladder cancer (MIBC) treated with neoadjuvant pembrolizumab or cisplatinbased chemotherapy before radical cystectomy (RC) | 1-gen-2024 | Mercinelli, C.; Raggi, D.; Cigliola, A.; Tateo, V.; Patane, D. A.; Crupi, E.; Colecchia, M.; Moschini, M.; Re, C.; Avesani, G.; Briganti, A.; Montorsi, F.; Ross, J. S.; Graf, R.; Pavlick, D. C.; Necchi, A. | |
| Data from Impact of Molecular Androgen and Estrogen Response Scores on Outcomes Following Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer | 1-gen-2025 | Tateo, Valentina; De Jong, Joep J.; Cigliola, Antonio; Maiorano, Brigida A.; Mercinelli, Chiara; Crupi, Emanuele; Giannatempo, Patrizia; Colecchia, Maurizio; Moschini, Marco; Proudfoot, James A.; Santini, Daniele; Davicioni, Elai; Briganti, Alberto; Montorsi, Francesco; Necchi, Andrea | |
| Data from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial | 1-gen-2023 | Basile, Giuseppe; Bandini, Marco; Gibb, Ewan A.; Ross, Jeffrey S.; Raggi, Daniele; Marandino, Laura; Costa De Padua, Tiago; Crupi, Emanuele; Colombo, Renzo; Colecchia, Maurizio; Lucianò, Roberta; Nocera, Luigi; Moschini, Marco; Briganti, Alberto; Montorsi, Francesco; Necchi, Andrea | |
| Distinct Gene Expression Patterns Identify Patients who Relapse After Neoadjuvant Pembrolizumab and Radical Cystectomy in the PURE-01 Study | 1-gen-2024 | Reike, M. J.; Raggi, D.; Mercinelli, C.; Cigliola, A.; Tateo, V.; Patanè, D. A.; Crupi, E.; De Padua, T. C.; Black, P. C.; Gibb, E. A.; Necchi, A. | |
| First results of NURE-Combo: A phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with muscle-invasive bladder cancer (MIBC) | 1-gen-2024 | Mercinelli, C.; Basile, G.; Raggi, D.; Cigliola, A.; Tateo, V.; Patanè, D. A.; Crupi, E.; Padua, T. C. D.; Colecchia, M.; Colombo, R.; Moschini, M.; Re, C.; Avesani, G.; Brembilla, G.; De Cobelli, F.; Briganti, A.; Pavlick, D. C.; Ross, J. S.; Montorsi, F.; Necchi, A. | |
| HER2 and urothelial carcinoma: current understanding and future directions | 1-gen-2026 | Raggi, Daniele; Crupi, Emanuele; Pederzoli, Filippo; Martini, Alberto; Briganti, Alberto; Alhalabi, Omar; O'Donnell, Peter H; Ross, Jeffrey; Gupta, Shilpa; Kamat, Ashish M; Faltas, Bishoy M; Black, Peter C; Spiess, Phillip E; Grivas, Petros; Gao, Jianjun; Apolo, Andrea B; Huddart, Robert A; Necchi, Andrea; Galsky, Matthew D | |
| Impact of Molecular Androgen and Estrogen Response Scores on Outcomes Following Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer | 1-gen-2025 | Tateo, V.; De Jong, J. J.; Cigliola, A.; Maiorano, B. A.; Mercinelli, C.; Crupi, E.; Giannatempo, P.; Colecchia, M.; Moschini, M.; Proudfoot, J. A.; Santini, D.; Davicioni, E.; Briganti, A.; Montorsi, F.; Necchi, A. | |
| Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review | 1-gen-2024 | Crupi, E.; Costa De Padua, T.; Marandino, L.; Fallara, G.; Pederzoli, F.; Cimadamore, A.; Goetz, E. C.; Cigliola, A.; Patane, D. A.; Mercinelli, C.; Tateo, V.; Salonia, A.; Briganti, A.; Montorsi, F.; Meeks, J. J.; Spiess, P. E.; Alhalabi, O.; Gao, J.; Kamat, A. M.; Grivas, P.; Necchi, A.; Raggi, D. | |
| Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI | 1-gen-2024 | Brembilla, G.; Basile, G.; Cosenza, M.; Giganti, F.; Del Prete, A.; Russo, T.; Pennella, R.; Lavalle, S.; Raggi, D.; Mercinelli, C.; Tateo, V.; Cigliola, A.; Patane, D.; Crupi, E.; Giannatempo, P.; Messina, A.; Calareso, G.; Martini, A.; Bandini, M.; Moschini, M.; Cardone, G.; Briganti, A.; Montorsi, F.; Necchi, A.; De Cobelli, F. | |
| Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial | 1-gen-2022 | Basile, Giuseppe; Bandini, Marco; Gibb, Ewan A; Ross, Jeffrey S; Raggi, Daniele; Marandino, Laura; Costa de Padua, Tiago; Crupi, Emanuele; Colombo, Renzo; Colecchia, Maurizio; Lucianò, Roberta; Nocera, Luigi; Moschini, Marco; Briganti, Alberto; Montorsi, Francesco; Necchi, Andrea | |
| Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial | 1-gen-2026 | Necchi, A.; De Jong, J. J.; Maiorano, B. A.; Proudfoot, J. A.; Basile, G.; Cigliola, A.; Mercinelli, C.; Tateo, V.; Piacentini, M.; Crupi, E.; Pastorino, G. L.; Latini, G.; Tomasi, E.; Davicioni, E.; Moschini, M.; Brembilla, G.; Colecchia, M.; De Cobelli, F.; Ross, J. S.; Madison, R.; Tambaoan, C. F. B.; Briganti, A.; Montorsi, F. | |
| Targeting HER2 in Urothelial Carcinoma: Why Histologic Subtypes and Divergent Histologies Matter | 1-gen-2026 | Crupi, Emanuele; Cigliola, Antonio; Mercinelli, Chiara; Piacentini, Michela; Serafin, Debora; Maiorano, Brigida A; Necchi, Andrea | |
| Targeting the Immune Checkpoint in Bladder Cancer | 1-gen-2025 | Mercinelli, C.; Tateo, V.; Crupi, E.; Cigliola, A.; Necchi, A. | |
| The role of androgen response pathway in association with tumor biology and response to neoadjuvant immune-checkpoint inhibitors (ICI) in muscle-invasive urothelial bladder carcinoma (MIBC) | 1-gen-2024 | Tateo, V.; Gibb, E.; Mercinelli, C.; Raggi, D.; Cigliola, A.; Patane, D. A.; Crupi, E.; Giannatempo, P.; Colecchia, M.; Moschini, M.; Avesani, G.; Briganti, A.; Montorsi, F.; Santini, D.; Necchi, A. | |
| Utility of fluoro-deoxy-glucose positron emission tomography (FDG-PET) to predict a pelvic lymph node involvement (LNI) in patients (pts) with muscle-invasive bladder cancer (MIBC) enrolled in neoadjuvant therapy trials | 1-gen-2024 | Cigliola, A.; Basile, G.; Mercinelli, C.; Raggi, D.; Tateo, V.; Patane, D. A.; Crupi, E.; Colecchia, M.; Colombo, R.; Avesani, G.; Re, C.; Briganti, A.; Montorsi, F.; Necchi, A. | |
| Vesical Imaging-Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer | 1-gen-2024 | Necchi, A.; Basile, G.; Gibb, E. A.; Raggi, D.; Calareso, G.; De Padua, T. C.; Patane, D.; Crupi, E.; Mercinelli, C.; Cigliola, A.; Tateo, V.; Giannatempo, P.; Moschini, M.; Briganti, A.; Montorsi, F.; Messina, A.; Ross, J. S.; Pavlick, D.; De Cobelli, F.; Brembilla, G. |